A possible involvement of the IκBζ pathway in IL-17A-induced hypercontractility.

<p>(<b>A</b>) Heatmap of genes expressed in MS after 24 h IL-17A treatment, assessed by microarray (n = 6). (<b>B</b>) Summary of changes of mRNA levels of the genes of IL-17A signalling cascade assessed by microarray (n = 6). Genes with significant changes in expression are coloured in red (increased) or blue (decreased). (<b>C</b>) Immunohistochemical staining for NFκB p65 protein in MS treated with or without IL-17A and IL-1β for 1 hr. Scale bars, 50 µm. (<b>D</b>) Immunofluorescence staining of NFκB p65 protein in primary cultured murine SMCs after 30 min treatment with IL-17A or IL-1β. Lower panels represent p65 immunosignal in the nuclei picked up automatically by the cell imaging system Celaview. Scale bar, 25 µm. (<b>E</b>) Relative intensity of NFκB p65 immunosignal accumulated in the nucleus treated with IL-17R-Fc-Chimera or IL17RC siRNA (n = 3∼6). (<b>F</b>) Time-dependent changes in mRNAs of NFκB proteins evaluated by real-time RT-PCR in mouse cultured SMCs (n = 6). Numerical data represent means ± s.e.m. *P<0.05, **P<0.01, ***p<0.001, Student's t-test (<b>E</b>, <b>F</b>) under the closed testing procedure for multiple comparison (<b>E</b>).